medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2022-16-6-116-121medsovet-6820Research ArticleГИНЕКОЛОГИЯGYNECOLOGYПа-де-де остеопороза и саркопении: остеосаркопенияA pas de deux of osteoporosis and sarcopenia: osteosarcopeniahttps://orcid.org/0000-0002-7430-1207ЯкушевскаяО. В.YakushevskayaO. V.

к.м.н., врач акушер-гинеколог, онколог, научный сотрудник отделения гинекологической  эндокринологии, 

117997, Москва, ул. Академика Опарина, д. 4

Cand. Sci. (Med.), Obstetrician-gynecologist, Oncologist, Researcher, Department of Gynecological Endocrinology,

4, Academician Oparin St., Moscow, 117997

aluckyone777@gmail.comhttps://orcid.org/0000-0003-2864-066XЮреневаС. В.YurenevaS. V.

д.м.н., ведущий научный сотрудник отделения гинекологической эндокринологии, 

117997, Москва, ул. Академика Опарина, д. 4

Dr. Sci. (Med.), Leading Researcher, Department of Gynecological Endocrinology, 

4, Academician Oparin St., Moscow, 117997

syureneva@gmail.comКомединаВ. И.KomedinaV. I.

акушер-гинеколог, аспирант отделения гинекологической эндокринологии, 

117997, Москва, ул. Академика Опарина, д. 4

Obstetrician-gynecologist, Postgraduate Student, Department of Gynecological Endocrinology,

4, Academician Oparin St., Moscow, 117997

komedina.veronika@gmail.comНациональный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. КулаковаРоссияKulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyRussian Federation20222504202206116121Copyright © Якушевская О.В., Юренева С.В., Комедина В.И., 20222022Якушевская О.В., Юренева С.В., Комедина В.И.Yakushevskaya O.V., Yureneva S.V., Komedina V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6820

Нарушения со стороны костно-мышечной системы в форме остеопороза (ОП) и саркопении (СП) широко распространены у пожилых людей. Растущий интерес к сочетанию ОП и СП продиктован более высоким уровнем низкоэнергетических переломов, что ведет к увеличению инвалидности, а также смертности, чем на фоне отдельных заболеваний. ОП и СП – это два состояния, которые связаны со старением и характеризуются одновременным снижением костной и мышечной массы. ОП и СП имеют общие факторы риска (генетические, эндокринные, диетические и условия образа жизни) и этиопатогенетические пути, что позволило объединить их в единый синдром, известный как остеосаркопения (ОСП). Среди гормональных факторов, которые играют ведущую роль в развитии и поддержании функционального состояния костной и мышечной ткани у женщин, необходимо выделить эстрогены. Дефицит эстрогенов в пери- и ранней постменопаузе ассоциирован с потерей минеральной плотности кости (МПК) и дегенеративными изменениями в скелетной мускулатуре. В настоящее время имеющиеся результаты исследований подтверждают протективный эффект менопаузальной гормональной терапии (МГТ) в отношении ОП. Данные, касающиеся СП, требуют проведения дополнительных исследований, и МГТ не должна быть рекомендована только лишь с  целью предотвращения потери мышечной массы у  женщин в  постменопаузе. Подтвержденный в исследованиях анаболический эффект эстрогенов предполагает благоприятное влияние как на мышцы, так и на кости, особенно в сочетании с физическими нагрузками. 

The growing interest in the tandem of osteoporosis and sarcopenia is dictated by a higher level of low-traumatic fractures, disability, and mortality than against the background of individual diseases. Osteoporosis and sarcopenia are associated with aging and are characterized by a simultaneous decrease in bone and muscle mass. Osteoporosis and sarcopenia share common risk factors (genetic, endocrine, dietary and lifestyle conditions) and etiopathogenetic pathways that combine diseases into a single syndrome known as osteosarcopenia. Among the hormonal factors that play a leading role in the development and maintenance of the functional state of bone and muscle tissue, it is necessary to single out estrogens. Currently available research results confirm the protective effect of hormone replacement therapy in relation to osteoporosis. Data on sarcopenia and hormone replacement therapy require further research. Correct understanding and application of therapeutic strategies is essential in order to stop the growing wave of low-traumatic fractures. 

низкотравматичные переломыриск переломовэстрогеныменопаузальная гормональная терапияостеосаркопенияlow-trauma fracturesfracture riskestrogenshormone replacement therapyosteosarcopeniaReferencesBarnsley J., Buckland G., Chan P.E., Ong A., Ramos A.S., Baxter M. et al. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021;33(4):759–715. https://doi.org/10.1007/s40520-021-01817-y.Barnsley J., Buckland G., Chan P.E., Ong A., Ramos A.S., Baxter M. et al. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021;33(4):759–715. https://doi.org/10.1007/s40520-021-01817-y.Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169.Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169.Inoue T., Maeda K., Nagano A., Shimizu A., Ueshima J., Murotani K. et al. Related Factors and Clinical Outcomes of Osteosarcopenia: A Narrative Review. Nutrients. 2021;13(2):291. https://doi.org/10.3390/nu13020291.Inoue T., Maeda K., Nagano A., Shimizu A., Ueshima J., Murotani K. et al. Related Factors and Clinical Outcomes of Osteosarcopenia: A Narrative Review. Nutrients. 2021;13(2):291. https://doi.org/10.3390/nu13020291.Keller K. Sarcopenia. Sarkopenie Wiener medizinische Wochenschrift. 2019;169:157–172. https://doi.org/10.1007/s10354-018-0618-2.Keller K. Sarcopenia. Sarkopenie Wiener medizinische Wochenschrift. 2019;169:157–172. https://doi.org/10.1007/s10354-018-0618-2.Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512–514. https://doi.org/10.1002/jcsm.12147.Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512–514. https://doi.org/10.1002/jcsm.12147.Curtis E., Litwic A., Cooper C., Dennison E.J. Determinants of Muscle and Bone Aging. J Cell Physiol. 2015;230(11):2618–2625. https://doi.org/10.1002/jcp.25001.Curtis E., Litwic A., Cooper C., Dennison E.J. Determinants of Muscle and Bone Aging. J Cell Physiol. 2015;230(11):2618–2625. https://doi.org/10.1002/jcp.25001.O’Caoimh R., Galluzzo L., Rodríguez-Laso Á., Van der Heyden J., Ranhoff A.H., Lamprini-Koula M. et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. Ann Ist Super Sanita. 2018;54(3):226–238. https://doi.org/10.4415/ann_18_03_10.O’Caoimh R., Galluzzo L., Rodríguez-Laso Á., Van der Heyden J., Ranhoff A.H., Lamprini-Koula M. et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. Ann Ist Super Sanita. 2018;54(3):226–238. https://doi.org/10.4415/ann_18_03_10.He B., Ma Y., Wang C., Jiang M., Geng C., Chang X. et al. Prevalence and Risk Factors for Frailty among Community-Dwelling Older People in China: A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2019;23(5):442–450. https://doi.org/10.1007/s12603-019-1179-9.He B., Ma Y., Wang C., Jiang M., Geng C., Chang X. et al. Prevalence and Risk Factors for Frailty among Community-Dwelling Older People in China: A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2019;23(5):442–450. https://doi.org/10.1007/s12603-019-1179-9.Sipilä S., Törmäkangas T., Sillanpää ., Aukee P., Kujala U.M., Kovanen V., Laakkonen E.K. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698–709. https://doi.org/10.1002/jcsm.12547.Sipilä S., Törmäkangas T., Sillanpää ., Aukee P., Kujala U.M., Kovanen V., Laakkonen E.K. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698–709. https://doi.org/10.1002/jcsm.12547.Hong A.R., Kim S.W. Effects of resistance exercise on bone health. Endocrinol Metab (Seoul). 2018;33(4):435–444. https://doi.org/10.3803/EnM.2018.33.4.435.Hong A.R., Kim S.W. Effects of resistance exercise on bone health. Endocrinol Metab (Seoul). 2018;33(4):435–444. https://doi.org/10.3803/ EnM.2018.33.4.435.Kaji H. Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Curr Opin Clin Nutr Metab Care. 2013;16(3):272–277. https://doi.org/10.1097/MCO.0b013e32835fe6a5.Kaji H. Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Curr Opin Clin Nutr Metab Care. 2013;16(3):272–277. https://doi.org/10.1097/MCO.0b013e32835fe6a5.Huang L.T., Wang J.H. The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia. Front Med (Lausanne). 2021;8:739251. https://doi.org/10.3389/fmed.2021.739251.Huang L.T., Wang J.H. The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia. Front Med (Lausanne). 2021;8:739251. https://doi.org/10.3389/fmed.2021.739251.Heino T.J., Chagin A.S., Sävendahl L. The novel estrogen receptor G-protein-coupled receptor 30 is expressed in human bone. J Endocrinol. 2008;197(2):R1–К6. https://doi.org/10.1677/JOE-07-0629.Heino T.J., Chagin A.S., Sävendahl L. The novel estrogen receptor G-protein-coupled receptor 30 is expressed in human bone. J Endocrinol. 2008;197(2):R1–К6. https://doi.org/10.1677/JOE-07-0629.Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., Дзеранова Л.К., Драпкина О.М. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4–47. https://doi.org/10.14341/osteo12930.Belaya Z.E., Belova K.Yu., Biryukova E.V., Dedov I.I., Dzeranova L.K., Drapkina O.M. et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4–47. (In Russ.) https://doi.org/10.14341/osteo12930.Kearns A.E., Khosla S, Kostenuik P.J. Receptor activator of nuclear factor jB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29(2):155–192. https://doi.org/10.1210/er.2007-0014.Kearns A.E., Khosla S, Kostenuik P.J. Receptor activator of nuclear factor jB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29(2):155–192. https://doi.org/10.1210/er.2007-0014.Drake M.T., Khosla S. Hormonal and systemic regulation of sclerostin. Bone. 2017;96:8–17. https://doi.org/10.1016/j.bone.2016.12.004.Drake M.T., Khosla S. Hormonal and systemic regulation of sclerostin. Bone. 2017;96:8–17. https://doi.org/10.1016/j.bone.2016.12.004.Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991–1997. https://doi.org/10.1210/jc.2009-2283.Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991–1997. https://doi.org/10.1210/jc.2009-2283.Weivoda M.M., Ruan M., Hachfeld C.M., Pederson L., Howe A., Davey R.A. et al. Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res. 2016;31(1):65–75. https://doi.org/10.1002/jbmr.2599.Weivoda M.M., Ruan M., Hachfeld C.M., Pederson L., Howe A., Davey R.A. et al. Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res. 2016;31(1):65–75. https://doi.org/10.1002/jbmr.2599.Hansen M. Female hormones: do they influence muscle and tendon protein metabolism?. Proc Nutr Soc. 2018;77(1):32–41. https://doi.org/10.1017/S0029665117001951.Hansen M. Female hormones: do they influence muscle and tendon protein metabolism?. Proc Nutr Soc. 2018;77(1):32–41. https://doi.org/10.1017/S0029665117001951.Forcina L., Miano C., Pelosi L., Musarò A. An overview about the biology of skeletal muscle satellite cells. Curr Genomics. 2019;20(1):24–37. https://doi.org/10.2174/1389202920666190116094736.Forcina L., Miano C., Pelosi L., Musarò A. An overview about the biology of skeletal muscle satellite cells. Curr Genomics. 2019;20(1):24–37. https://doi.org/10.2174/1389202920666190116094736.Collins B.C., Arpke R.W., Larson A.A., Baumann C.W., Xie N., Cabelka C.A. et al. strogen Regulates the Satellite Cell Compartment in Females. Cell Rep. 2019;28(2):368–381.e6. https://doi.org/10.1016/j.celrep.2019.06.025.Collins B.C., Arpke R.W., Larson A.A., Baumann C.W., Xie N., Cabelka C.A. et al. strogen Regulates the Satellite Cell Compartment in Females. Cell Rep. 2019;28(2):368–381.e6. https://doi.org/10.1016/j.celrep.2019.06.025.Collins B., Laakkonen E., Lowe D. Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength. Bone. 2019;123:137–144. https://doi.org/10.1016/j.bone.2019.03.033.Collins B., Laakkonen E., Lowe D. Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength. Bone. 2019;123:137–144. https://doi.org/10.1016/j.bone.2019.03.033.Smith G.I., Yoshino J., Reeds D.N., Bradley D., Burrows R.E., Heisey H.D. et al. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014;99(1):256–265. https://doi.org/10.1210/jc.2013-2835.Smith G.I., Yoshino J., Reeds D.N., Bradley D., Burrows R.E., Heisey H.D. et al. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014;99(1):256–265. https://doi.org/10.1210/jc.2013-2835.Hansen M., Skovgaard D., Reitelseder S., Holm L., Langbjerg H., Kjaer M. Effects of estrogen replacement and lower androgen status on skeletal muscle collagen and myofibrillar protein synthesis in postmenopausal women. J Gerontol A Biol Sci Med Sci. 2012;67(10):1005. https://doi.org/10.1093/gerona/gls007.Hansen M., Skovgaard D., Reitelseder S., Holm L., Langbjerg H., Kjaer M. Effects of estrogen replacement and lower androgen status on skeletal muscle collagen and myofibrillar protein synthesis in postmenopausal women. J Gerontol A Biol Sci Med Sci. 2012;67(10):1005. https://doi.org/10.1093/gerona/gls007.Bilodeau P., Coyne E., Wing S. The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. Am J Physiol Cell Physiol. 2016;311(3):C392–C403. https://doi.org/10.1152/ajpcell.00125.2016.Bilodeau P., Coyne E., Wing S. The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. Am J Physiol Cell Physiol. 2016;311(3):C392–C403. https://doi.org/10.1152/ajpcell.00125.2016.Kangas R., Pöllänen E., Rippo M.R., Lanzarini C., Prattichizzo F., Niskala P. et al. Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs. Mech Ageing Dev. 2014;143–144:1–8. https://doi.org/10.1016/j.mad.2014.11.001.Kangas R., Pöllänen E., Rippo M.R., Lanzarini C., Prattichizzo F., Niskala P. et al. Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs. Mech Ageing Dev. 2014;143–144:1–8. https://doi.org/10.1016/j.mad.2014.11.001.Geraci A., Calvani R., Ferri E., Marzetti E., Arosio B., Cesari M. Sarcopenia and Menopause: The Role of Estradiol. Front Endocrinol (Lausanne). 2021;12:682012. https://doi.org/10.3389/fendo.2021.682012.Geraci A., Calvani R., Ferri E., Marzetti E., Arosio B., Cesari M. Sarcopenia and Menopause: The Role of Estradiol. Front Endocrinol (Lausanne). 2021;12:682012. https://doi.org/10.3389/fendo.2021.682012.Юренева С.В., Якушевская О.В. Перименопауза – золотое время для профилактики заболеваний, ассоциированных с возрастом. Эффективная фармакотерапия. 2021;17(13):36–45. Режим доступа: https://umedp.ru/articles/perimenopauza_zolotoe_vremya_dlya_profilaktiki_zabolevaniy_assotsiirovannykh_s_vozrastom.html.Yureneva S.V., Yakushevskaya O.V., Komedina V.I. Perimenopause is a golden time for the prevention of age-related diseases. Effective Pharmacotherapy. 2021;17(13):36–45. (In Russ.) Available at: https://umedp.ru/articles/perimenopauza_zolotoe_vremya_dlya_profilaktiki_zabolevaniy_assotsiirovannykh_s_vozrastom.html.Javed A.A., Mayhew A.J., Shea A.K., Raina P. Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8):e1910154. https://doi.org/10.1001/jamanetworkopen.2019.10154.Javed A.A., Mayhew A.J., Shea A.K., Raina P. Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8):e1910154. https://doi.org/10.1001/jamanetworkopen.2019.10154.Ronkainen P.H., Kovanen V., Alén M., Pöllänen E., Palonen E.M., AnkarbergLindgren C. et al. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J Appl Physiol. 2009;107(1):25–33. https://doi.org/10.1152/japplphysiol.91518.2008.Ronkainen P.H., Kovanen V., Alén M., Pöllänen E., Palonen E.M., AnkarbergLindgren C. et al. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J Appl Physiol. 2009;107(1):25–33. https://doi.org/10.1152/japplphysiol.91518.2008.Sipilä S., Taaffe D.R., Cheng S., Puolakka J., Toivanen J., Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebocontrolled study. Clin Sci (Lond). 2001;101(2):147–157. Available at: https://pubmed.ncbi.nlm.nih.gov/11473488.Sipilä S., Taaffe D.R., Cheng S., Puolakka J., Toivanen J., Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebocontrolled study. Clin Sci (Lond). 2001;101(2):147–157. Available at: https://pubmed.ncbi.nlm.nih.gov/11473488.Kim S.W., Kim R. The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 2008–2011. Menopause. 2020;27(5):506–511. https://doi.org/10.1097/GME.0000000000001509.Kim S.W., Kim R. The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 2008–2011. Menopause. 2020;27(5):506–511. https://doi.org/10.1097/GME.0000000000001509.Lowe D., Baltgalvis K., Greising S. Mechanisms behind estrogen’s beneficial effect on muscle strength in females. Exerc Sport Sci Rev. 2010;38(2):61–67. https://doi.org/10.1097/JES.0b013e3181d496bc.Lowe D., Baltgalvis K., Greising S. Mechanisms behind estrogen’s beneficial effect on muscle strength in females. Exerc Sport Sci Rev. 2010;38(2):61–67. https://doi.org/10.1097/JES.0b013e3181d496bc.Cariati I., Bonanni R., Onorato F., Mastrogregori A., Rossi D., Iundusi R. et al. Role of Physical Activity in Bone-Muscle Crosstalk: Biological Aspects and Clinical Implications. J Funct Morphol Kinesiol. 2021;6(2):55. https://doi.org/10.3390/jfmk6020055.Cariati I., Bonanni R., Onorato F., Mastrogregori A., Rossi D., Iundusi R. et al. Role of Physical Activity in Bone-Muscle Crosstalk: Biological Aspects and Clinical Implications. J Funct Morphol Kinesiol. 2021;6(2):55. https://doi.org/10.3390/jfmk6020055.Pöllänen E., Fey V., Törmäkangas T., Ronkainen P.H., Taaffe D.R., Takala T. et al. Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle. Age (Dordr). 2010;32(3):347–363. https://doi.org/10.1007/s11357-010-9140-1.Pöllänen E., Fey V., Törmäkangas T., Ronkainen P.H., Taaffe D.R., Takala T. et al. Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle. Age (Dordr). 2010;32(3):347–363. https://doi.org/10.1007/s11357-010-9140-1.Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. https://doi.org/10.3109/13697137.2015.1129166.Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. https://doi.org/10.3109/13697137.2015.1129166.de Villiers T.J., Goldstein S.R. Update on bone health: the International Menopause Society White Paper 2021. Climacteric. 2021;24(5):498–504. https://doi.org/10.1080/13697137.2021.1950967.de Villiers T.J., Goldstein S.R. Update on bone health: the International Menopause Society White Paper 2021. Climacteric. 2021;24(5):498–504. https://doi.org/10.1080/13697137.2021.1950967.Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973–997. https://doi.org/10.1097/GME.0000000000001831.Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973–997. https://doi.org/10.1097/GME.0000000000001831.Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteop Int. 2019;30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5.Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteop Int. 2019;30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5.Dent E., Morley J.E., Cruz-Jentoft A.J., Woodhouse L., Rodríguez-Mañas L., Fried L.P. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. J Nutr Health Aging. 2019;23(9):771–787. https://doi.org/10.1007/s12603-019-1273-z.Dent E., Morley J.E., Cruz-Jentoft A.J., Woodhouse L., Rodríguez-Mañas L., Fried L.P. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. J Nutr Health Aging. 2019;23(9):771–787. https://doi.org/10.1007/s12603-019-1273-z.

The authors declare that there are no conflicts of interest present.